Requires hospitals to test for fentanyl and xylazine as part of urine drug screenings.

This bill requires New Jersey hospitals to include fentanyl and xylazine testing in standard urine drug screenings when conducted for patient diagnosis. It directly affects licensed general acute care hospitals that perform such screenings. Hospitals must report de-identified positive results for either drug to the state Department of Health, without altering existing opioid or overdose reporting requirements. The goal is to improve overdose treatment by providing healthcare workers with critical drug detection data and to help the state track the spread of these dangerous substances.